November 09, 2026
In her monthly column "Cell Notes," AABB's Christina Celluzzi, PhD, MS, CABP(H), shares insights, findings and commentary on emerging topics in biotherapies. Subscribe to CellSource to receive "Cell Notes" and biotherapies updates from AABB directly in your inbox.
Fresh from the 2026 AABB Annual Meeting in Atlanta, I extend a heartfelt thank you to everyone who attended, contributed their expertise, and helped make this year’s meeting such a rewarding experience. The exchange of ideas, enthusiasm and shared commitment to advancing our field were wonderful reminders of what makes the AABB community so special.
That same spirit of discovery and collaboration also highlights an important reality: as science advances, the frameworks that guide its application must evolve alongside it.
Every generation of medicine reaches a point where innovation begins to outpace the systems designed to oversee it. Blood banking did. Organ transplantation did. Molecular diagnostics did. Today, cell and gene therapies are doing the same.
The challenge is familiar: How do we encourage innovation while preserving the quality and safety that patients expect?
History suggests the answer is rarely to abandon established principles. Instead, we adapt them. Regulation evolves not because quality standards become less important, but because innovation continually changes how those standards are applied.
During a presentation to the AABB Asia-Pacific Group this summer, Wanxing Cui, MD, PhD, CABP(H), director of the cell therapy manufacturing facility at MedStar Georgetown University Hospital, provided a timely illustration of this evolution through an overview of China’s Decrees 818 and 828. Cui’s presentation prompted me to reflect on a much broader challenge facing our profession: how regulatory thinking can keep pace with scientific innovation.
Throughout the world, regulators are exploring new ways to support increasingly personalized therapies while maintaining rigorous oversight. China’s Decree 818, effective May 2026, establishes a dual-track framework. Alongside the traditional drug pathway through the National Medical Products Administration (NMPA), which was itself recently updated by Decree 828, it creates a technology pathway overseen by the National Health Commission (NHC). Under this pathway, qualified Grade 3A hospitals may research and, once approved, deliver certain personalized therapies as medical services rather than marketed drug products, under defined quality, manufacturing, ethics and clinical oversight requirements.
Although these approaches differ, both are grounded in the same objective: protecting patients while enabling innovation. Whether this particular model influences other regions remains to be seen. That is almost beside the point. The broader lesson is that regulation is evolving alongside the science.
As therapies become more personalized, manufacturing becomes more sophisticated, and clinical care becomes increasingly individualized, regulators everywhere will continue asking difficult questions. What evidence is appropriate? How should quality be demonstrated? Where should therapies be manufactured? How can innovation reach patients more efficiently without compromising safety?
These questions are not unique to one country. They are becoming universal.
Fortunately, while regulatory pathways may differ, the principles that define quality remain remarkably consistent. Donor qualification, validated processes, traceability, quality management systems, competent personnel and continuous oversight remain the foundation upon which safe and effective therapies are built. Those principles transcend geography, healthcare systems and regulatory structures.
Perhaps that is the most important takeaway.
These three ideas are inseparable. Innovation creates possibilities. Regulation provides the framework that translates those possibilities into responsible clinical practice. Quality provides the confidence that allows patients, health care professionals, regulators and the public to trust the outcome.
For organizations like AABB, this perspective has always mattered. Our role is not simply to follow regulatory change, but to help the community understand it, prepare for it, and apply enduring quality principles regardless of where innovation leads next.
As our field continues to evolve, so must we. That means being:
Innovation will continue to move faster than any regulatory framework can fully anticipate. That is not a weakness of regulation. It is the nature of scientific discovery. The real measure of a regulatory system is not whether it predicts every breakthrough, but whether it can evolve without compromising the principles that matter most. As cell therapies become increasingly personalized, decentralized and globally connected, the conversation will no longer be about choosing between innovation and quality.
It will be about ensuring they evolve together.
For AABB members interested in learning more, Dr. Cui’s presentation, “China’s Dual-Track Framework for Cell Therapy” presented to the AABB Asia-Pacific Group, is available in the Projects page section of the AABB website as a benefit to AABB members.
To learn more about AABB’s Quality Systems Essentials, the framework underlying all AABB Standards, visit AABB’s Updated Quality Systems Essentials page. The AABB Quality Systems Essentials are also available in book form.